

SCIENTIFIC PLANNING COMMITTEE DISCLOSURE OF COMMERCIAL INTEREST

DR. DANIEL NGUI

Relationships with commercial interests:

- Grants/Research Support: Amgen, Lundbeck, Merck, Mylan, AstraZeneca, Lilly/Boehringer Ingelheim, Pfizer
- Speakers Bureau/Honoraria: Amgen, AstraZeneca, BMS/Pfizer, Lilly/Boehringer Ingelheim, Novo Nordisk,
- Consulting Fees : CHRC, CCRN, MDBriefcase, Lilly/Boehringer Ingelheim
- Investments: Healthchoicefirst.com
- Clinical Trial: single trial HTN
- Non-for-profit relationship: CCRN
- Advisory board member: Amgen, AstraZeneca, BMS/Pfizer, Eli Lilly, Novo Nordisk, Lundbeck, Janssen

DISCLOSURE OF COMMERCIAL SUPPORT

This program has received financial support from Amgen in the form of an educational grant.

This program has received in-kind support from Amgen in the form of logistical support.

Potential for conflict(s) of interest:

- Dr. Daniel Ngui has received payment/funding from companies whose product(s) are being discussed in this program
 - Amgen

MITIGATING POTENTIAL BIAS

- All content has been reviewed by a physician steering committee and the College of Family Physicians Canada
- All data has been sourced from evidence that is clinically accepted
- All support used in justification of patient care recommendations conform to generally accepted standards